Topical Cyclosporine-A for Management of Epiphora in Eyes With Acquired Punctal Stenosis
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Epiphora grading
研究概览
简要总结
to investigate the clinical outcomes and tolerances of Cyclosporine A (CsA) in treating epiphora in eyes with acquired punctum stenosis
详细描述
a prospective study included patients who were referred to our outpatient clinics in Farwanyia hospital, Kuwait during the period between July 2019 and January 2020, having symptomatic epiphora associated with severe acquired lower punctal stenosis. Patients were treated with topical 0.05% CsA on twice daily dose with topical preservative free artificial tears Q.I. D. Patients were followed up monthly for at least 3 months by epiphora grading, Fluorescein dye disappearance test (FDT) and evaluating the patient satisfaction
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients of either sex
- •had a diagnosis of epiphora that persisted more than three months both indoors and outdoors
- •grade 0 punctal stenosis
- •did not adequately respond to artificial tears, topical corticosteroids and topical antibiotics or in whom corticosteroids were discontinued due to their side effects.
排除标准
- •congenital punctal obstruction
- •edematous puncti
- •allergic conjunctivitis
- •history of dacryocystitis,
- •inflammatory systemic diseases
- •any previous chemotherapy treatment, and local irradiation.
- •other causes of epiphora, lid laxity, entropion, and ectropion
- •lid malposition, canalicular or nasolacrimal sac or duct obstruction
- •previous eyelid or lacrimal drainage surgery
- •untreated conjunctivitis or blepharitis
研究组 & 干预措施
Cyclosporine A
All patients were treated with topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California) on twice daily dose, in addition to the topical preservative free artificial tears Q.I. D.
干预措施: topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose, (Drug)
结局指标
主要结局
Epiphora grading
时间窗: 3 months
Munk grading system score from 0 to 5 the higher the worse
次要结局
- Fluorescein dye disappearance test (FDT)(3 months)
研究者
Mona A Nassief
lecturer of ophthalmology Mansoura University Egypt currentlty working as senior registrar in Farwaniya Hospital
Farwaniya Hospital
